Lila Sciences Stock Price, Valuation & IPO
Private company — Lila Sciences is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.
Status source: AXEVIL investment team
$13.92 per share (AXEVIL consensus estimate)
Source: AXEVIL consensus of recent secondary transactions · as of 27 October 2026
Last round valuation: $8.5B
Source: B-1, July 2026, post-money
Total raised: $550M
Data last updated: 27 October 2026
About Lila Sciences
Incubated by Flagship Pioneering. Builds an AI platform paired with fully autonomous laboratories: the system generates its own hypotheses and runs real experiments in biology, chemistry, and materials science. Operates through partnerships rather than its own drug pipeline.
Lila Sciences is a US company building AI for autonomous science: a model proposes a hypothesis, a robotic lab runs the experiment, and the result immediately feeds back into training the next model version. Founded in 2023 inside Flagship Pioneering, the creator of Moderna, and headquartered in Cambridge. It works across biology, chemistry, and materials science; results so far include a palladium catalyst that could reduce hydrogen production's dependence on iridium. The company leases its platform to pharmaceutical and chemical companies, and under its Creation model hands a partner a finished, patented molecule or material while retaining a share of future sales. Since emerging from stealth in March 2025, it has raised $550 million, with its post-Series A valuation exceeding $1.3 billion.
- Sector: AI / Science
- Headquarters: Cambridge, Massachusetts, USA
- Founded: 2023
Key highlights
- Corporations leasing the platform. Pharmaceutical and chemical companies can buy experiments run in Lila's labs instead of building their own. This is recurring revenue that grows with the customer count, and the company began onboarding its first customers in October 2025.
- Proprietary assets and new companies. Under its Creation model, Lila hands a partner a finished, patented molecule or material and can retain a share of future sales. Flagship has a track record of spinning such discoveries into standalone companies — that's how Moderna and Generate:Biomedicines came about.
- Expansion into energy and chemicals. The palladium catalyst could reduce hydrogen production's reliance on iridium, of which only a few tons are mined worldwide each year. The team says the same experimental approach applies to green ammonia and plastics feedstock.
- Lab scale. A move into a roughly 23,000 sq m campus allows a multi-fold increase in the number of AI-operated instruments. Each new instrument generates data that improves the model across every research area at once.
- Government contracts. Three Genesis Mission projects could move to a second phase with larger funding. Working with national labs opens a path to defense and semiconductor contracts, an area where Lila already has a dedicated business line.
- Alliance with NVIDIA. NVIDIA's venture fund has taken an equity stake, and Lila builds its AI agents on the NVIDIA BioNeMo stack. Access to compute and joint development accelerate training of a model that needs capacity on the scale of the largest language models.
Funding rounds
| Date | Round | Price / share | Post-money valuation |
|---|---|---|---|
| 31 July 2026 | B-1 | $11.27 | $8.5B |
| 14 October 2025 | A | $2.19 | $1.4B |
Frequently asked questions
How can I buy Lila Sciences stock before the IPO?
Not on a public exchange — Lila Sciences is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.
What is the Lila Sciences stock price?
A private company has no single official share price. AXEVIL's consensus estimate is $13.92 per share as of 27 October 2026. Its most recent round implied a post-money valuation of $8.5B (July 2026).
What is Lila Sciences's valuation (net worth)?
Lila Sciences's most recent funding round valued the company at $8.5B post-money (July 2026) — the latest primary-market measure of what the company is worth. Secondary trades can price its shares above or below that round.
When will Lila Sciences IPO?
No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.
Is Lila Sciences publicly traded?
No. Lila Sciences is a private company and its shares are not listed on any public exchange.
Does Lila Sciences have a stock symbol?
No. Lila Sciences has no ticker symbol because its shares are not listed on any exchange; a symbol is assigned only at an IPO or direct listing.
Similar companies
- Periodic Labs — AI / Science
- Bolt Mobility — Mobility / Fintech
- Chainalysis — Data / Analytics
- Together AI — Artificial Intelligence
- Wayve — Transportation
- Flock Safety — Enterprise Software
Risk disclosure
Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Valuations and share prices shown here are AXEVIL estimates built from primary sources — filings, announced rounds and completed secondary transactions — not quoted market prices, and they can be revised. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.